Hua Zhang PhD 1 , Jeffrey L. Bennett MD, PhD 2 , A. S
? NARCOMS Report-2007 Registry Update Optic Neuritis in Multiple Sclerosis ? Neuromyelitis Optica Dean M. Wingerchuk, MD, MSc, FRCP(C) A Historical Perspective on NMO Neuromyelitis optica (NMO), also known as Devic’s disease, was identified more than one hundred years ago as a severe disorder affecting the spinal cord (causing paralysis) and both optic nerves (causing blindness).
Neuromyelitis optica (NMO) is an autoimmune demyelinating disease characterized by the presence of anti-aquaporin-4 (AQP4) antibodies in the patient sera. We recently reported that these autoantibodies are able to bind AQP4 when organized in the supramolecular structure called the orthogonal array of particles (OAP).
Neuromyelitis optica (NMO) is an inflammatory demyelinating disease of spinal cord and optic nerve caused by pathogenic autoantibodies (NMO-IgG) against astrocyte aquaporin-4 (AQP4). We developed a high-throughput screen to identify blockers of NMO-IgG binding to human AQP4 using a human recombinant monoclonal NMO-IgG and transfected Fisher rat thyroid cells stably expressing human M23-AQP4
OBJECTIVE:To describe the clinical, molecular, and neuropathological findings of a patient with aquaporin 4-positive relapsing myelitis who developed extensive brain involvement followed by death. DESIGN: Case report.
Neuromyelitis optica (NMO) is an inflammatory disease affecting the optic nerve and spinal cord, in which autoantibodies against aquaporin 4 (AQP4) water channel protein probably play a pathogenic role. Here we show that a B-cell subpopulation, exhibiting the CD19intCD27highCD38highCD180− phenotype, is selectively increased in the peripheral blood of NMO patients and that anti-AQP4 antibodies (AQP4-Abs) are mainly produced by these cells in the blood of these patients. These B cells showed the morphological as well as the phenotypical characteristics of plasmablasts (PB) and were further expanded during NMO relapse
For patients with relapsing-remitting multiple sclerosis (RRMS), there are currently six approved medications that have been shown to alter the natural course of the disease. The approved medications include three beta interferon formulations, glatiramer acetate, natalizumab and mitoxantrone.
The complement system is essential in the pathogenesis of inflammatory central nervous system disorders.
Neuromyelitis optica (NMO, Devic’s disease), an uncommon demyelinating neuro-immunological disease, can be associated with autoimmune diseases. In SLE associated forms anti-aquaporin-4 antibody positivity can help differentiating between SLE nerve system manifestation and NMO.
BACKGROUND: Antibodies targeting membrane proteins play an important role in various autoimmune diseases of the nervous system.
Background: Optic neuritis (ON) is a common first demyelinating event in multiple sclerosis (MS), and one of absolute clinical events to diagnose neuromyelitis optica (NMO). However, it seemed not all ON attacks are clinically evident.
Background: Acute transverse myelitis (ATM) in patients with no history of central nervous system (CNS) demyelinating disease may be idiopathic or herald the development of neuromyelitis optica spectrum disorder (NMOSD) or multiple sclerosis (MS). NMOSD may differ from MS in pathogenesis, prognosis and response to treatment, and radiological features at the first presentation of ATM that distinguish between NMOSD and MS would be desirable